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Abstract
Background: There have been several reports on dasatinib-induced reversible pulmonary hypertension. This is the
first reported case in Latvia; the patient did not discontinue the drug after the first adverse effects in the form of
pleural effusions, which we speculate led only to partial reversion of the disease.
Case presentation: A 67-year-old white man with chronic myelogenous leukemia was treated with the dual Src
and BCR-ABL tyrosine kinase inhibitor dasatinib. After treatment with dasatinib he had multiple pleural effusions
which were suspected to be caused by congestive heart failure. Later a transthoracic Doppler echocardiography
and right-sided heart catheterization revealed severe pulmonary hypertension with pulmonary vascular resistance of
12 Wood units and mean pulmonary artery pressure of 53 mmHg. Computed tomography ruled out a possible
pulmonary embolism; laboratory specific tests for human immunodeficiency virus, rheumatoid factor, and anti-nuclear
antibodies were negative, and dasatinib-induced pulmonary arterial hypertension was diagnosed.
A follow-up right-sided heart catheterization and 6-minute walk test done a month after the discontinuation of
dasatinib showed significant improvement: mean pulmonary artery pressure of 34 mmHg and pulmonary vascular
resistance of 4 Wood units.
Conclusions: Patients should always be closely monitored when using dasatinib for a prolonged time.
Dasatinib-induced pulmonary hypertension may be fully reversible after the therapy is suspended, but the key
factors involved are still unclear and need to be further studied.
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Background
Pulmonary hypertension (PH) is defined as an increase
in mean pulmonary arterial pressure (mPAP) ≥ 25
mmHg at rest as assessed by right-sided heart
catheterization (RHC). Normal mPAP at rest is 14 ± 3
mmHg with an upper limit of normal of approximately
20 mmHg.
The clinical classification of PH is intended to
categorize multiple clinical conditions into five groups
according to their similar clinical presentation, patho-
logical findings, hemodynamic characteristics, and treat-
ment strategy. Group 1, pulmonary arterial hypertension
(PAH), includes precapillary PH, with a normal pulmon-
ary capillary wedge pressure (PCWP) ≤ 15 mmHg, which
is idiopathic, heritable, drug induced, or associated with
various conditions; group 2 includes postcapillary PH as-
sociated with left-sided heart disease; group 3 corre-
sponds to PH due to chronic lung diseases; group 4
corresponds to chronic thromboembolic PH; and group
5 consists of several forms of PH for which the patho-
genesis is unclear or multifactorial [1].
Chronic myelogenous leukemia (CML) in the
chronic phase (CP), a clonal myeloproliferative dis-
order, is caused by the constitutively active BCR-ABL
tyrosine kinase resulting from the translocation that
produces the Philadelphia (Ph) chromosome. Imatinib,
an inhibitor of the BCR-ABL kinase (tyrosine kinase
inhibitor, TKI), was the standard first-line therapy for
patients with CML-CP for many years. Resistance to
imatinib led to the development of novel TKIs such
as dasatinib and nilotinib (second-generation BCR-ABL
TKIs). Other TKIs with activity in CML include bosutinib
and ponatinib [2–4]. Dasatinib therapy induces a complete
cytogenetic response in approximately 50% of patients
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who do not have a response to imatinib or cannot tolerate
it [5].
Compared with imatinib, dasatinib is associated with
higher rates of pleural effusion, thrombocytopenia, and
in rare cases PH, but lower rates of edema, gastrointes-
tinal adverse events (AEs), musculoskeletal AEs, and
rash [6]. The 2015 European Society of Cardiology
guidelines for the diagnosis and treatment of PH in-
cludes dasatinib in the category of drugs that are “likely
to induce pulmonary hypertension” [1].
There have been several reports on dasatinib-induced
reversible PH [3]. This case is unique, as it is the first re-
ported case in Latvia, and the patient did not discon-
tinue the drug after the first adverse effects in the form
of pleural effusions, which we speculate led only to par-
tial reversion of the disease.
Case presentation
Our patient is a 67-year-old white man, who works as a
teacher in a small city. He does not smoke tobacco; he
has a history of arterial hypertension grade I to II and
coronary heart disease. His mother died from myocardial
infarction due to occlusive coronary artery disease. He
was diagnosed as having CML in 2006. The treatment
was initially started with imatinib (Glivec, Novartis) 400
mg administered orally once daily. Imatinib 400 to 800
mg per day was taken for 53 months. He lost major mo-
lecular response (MMR) and imatinib therapy was re-
placed with dasatinib 100 mg orally administered once
daily and after 6 months MMR was achieved. He was
also using torasemide 20 mg orally administered once
daily and metoprolol succinate 50 mg orally adminis-
tered once daily. In April 2015 he developed increasing
dyspnea on exertion, fatigue, and peripheral edema. He
consulted his family physician, and a chest X-ray was
done, confirming pleural effusion. On admission his
heart rate was 97 beats per minute and blood pressure
was 143/90 mmHg. Fever was not present. He presented
with peripheral edema and diminished breath sounds.
Pleural friction rub was present. Deformity of the spine
accompanied by lower back pain was noted during
neurological check-up. The pleural fluid was drawn out
several times via thoracentesis (1.5 to 2 liters of exudate
in total) but cytological analysis excluded malignancy, a
GeneXpert® tuberculosis test of a bronchial smear was
also negative, therefore, the pleural effusion was sus-
pected to be caused by congestive heart failure. A
complete blood count was normal, but his creatinine
levels were elevated (Tables 1 and 2). Over the course of
the next 4 months his general condition deteriorated as
he experienced multiple recurrences of pleural effusion
requiring drainage of the built-up fluid (Table 3). Dasati-
nib therapy was stopped in September 2015 after 42
months of treatment. A coronarography was done in
September 2015; it did not reveal any hemodynamically
important stenosis in his coronary arteries, thereby ex-
cluding coronary artery disease. An echocardiogram
showed right ventricular dilation, estimated right ven-
tricle systolic pressure of 125 mmHg, and severe tricus-
pid regurgitation suggesting PH.
RHC performed on 12 October 2015 revealed severe
PAH with mPAP of 53 mmHg and normal left ventricle
diastolic pressure (Table 4). A computed tomography
scan confirmed the absence of pulmonary embolism; la-
boratory specific tests for HIV, rheumatoid factor, and
anti-nuclear antibodies (ANA) were negative and
dasatinib-induced PAH was diagnosed. The 6-minute
walk test (6MWT) distance was limited to 165 m
(Table 5). He started PAH-targeted treatment with sil-
denafil 20 mg × 3 orally administered and restarted
CML therapy with imatinib 400 mg orally administered
daily on 19 October 2015.
His condition rapidly improved, a check-up RHC done
a month later showed mPAP of 34 mmHg, decreased
pulmonary vascular resistance, and increased cardiac
Table 1 Complete blood count
Date 29 April 2015 19 February 2016
Erythrocytes, × 106mm3 5.29 4.91
Leukocytes, × 103mm3 3.66 4.3
Hemoglobin, g/dl 12.6 13.1
Hematocrit, % 38.8 41.5
Platelets, × 103mm3 239 256
MCV, fL 84 82
MCH, pg 29.2 28.9
MCHC, g/dl 34.9 35.4
Neu, % 55.5 68.3
Ly, % 35.0 20.7
Eo, % 0.5 0.9
Ba, % 0 0
Mo, % 8.5 9.5
Ba basophils, Eo eosinophils, Ly lymphocytes, MCH mean corpuscular
hemoglobin, MCHC mean corpuscular hemoglobin concentration, MCV mean
corpuscular volume, Mo monocytes, NEU neutrophils
Table 2 Biochemistry of serum
Date 29 April 2015 19 February 2016
ALT, U/l 17.2 13.4
AST, U/l 5.0 3.3
Urea, mmol/l 14.7 12.2
Creatinine, μmol/l 187 87
Glucose, mmol/l 5.53 5.33
Total bilirubin, μmol/l 11.8 11.1
Direct bilirubin, μmol/l 5.6 5.2
ALT alanine aminotransferase, AST aspartate aminotransferase
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output values (Table 4). His 6MWT score was 2.1 times
higher (Table 5). Echocardiography done in February
2016 revealed right ventricle systolic pressure of 50
mmHg; a complete blood count and biochemistry
showed no abnormalities (Tables 1 and 2). He has been
asymptomatic since, but treatment for PAH with silden-
afil is still necessary. The last hematological check-up
was in January 2017, he was still on imatinib 400 mg
daily and had normal complete blood count and MMR
(BRA-ABL was negative).
Discussion
Our case provides insight on the chain of events that
can occur in patients using long-term therapy with dasa-
tinib, ultimately leading to partially reversible PAH. It
raises awareness and adds data for future studies of this
drug, as its usage and novel applications grow. Patients
with CML in the European Union are mostly treated ac-
cording to European LeukemiaNet recommendations,
concerning the use of the five available TKIs, the evalu-
ation of cytogenetic and molecular response, and the
strategy of treatment [7]. Three TKIs (imatinib, nilotinib,
dasatinib) are recommended first-line treatments.
Dasatinib is indicated for patients with newly diag-
nosed CML-CP or patients with CML in any phase who
are resistant or intolerant to prior therapy [4, 7, 8]; this
was the reason it was prescribed in our case. Each of the
TKIs has typical AEs. Dasatinib often is associated
with recurring pleural effusions, headaches, fatigue,
dyspnea, and, in rare cases, PAH. It should also be
noted that the therapy needs to be immediately sus-
pended in patients with pleural effusions [9]. The
connection between the recurring pleural effusions
and dasatinib therapy was considered too late in our
case, after our patient had gone through multiple
hospitalizations, thoracenteses, and developed severe
PH. His symptoms and overall condition greatly im-
proved a month after discontinuation of the drug,
confirming that dasatinib-induced PAH is reversible.
Nevertheless a complete recovery was not observed,
suggesting that some degree of pulmonary vascular
remodeling had occurred. There have been reports of
cases where a full recovery was achieved in patients
with dasatinib-induced PAH but there is no informa-
tion on whether the extent of recovery depends on
the duration of therapy or individual risk factors.
The case presented is consistent with other reports of
dasatinib-related PAH [3]. In all of these cases the pa-
tients were using dasatinib for a prolonged time (19 to
52 months), developed pleural effusions, and had a sud-
den onset of pulmonary vasculopathy and a rapid recov-
ery after the discontinuation of the drug, which is not
typical in patients with PAH. This leads to the conclu-
sion that the pathophysiological mechanism differs from
the typical vascular alterations seen in patients with
PAH. Since the exact mechanism is still unknown, ef-
fective biomarker-based screening options and
mechanism-based treatment are not available for pa-
tients with dasatinib-induced PAH. A better understand-
ing of the pathophysiological mechanism would possibly
create new treatment options in these patients, as well
as increase our understanding of processes involved in
the development of PAH.
Table 3 Biochemistry data of pleural fluid
Date 29 April 2015 08 May 2015 11 August 2015
Total serum protein, g/l 67.1 69.4 64.3
Serum LDH, U/l 303 296 320
Pleural fluid protein, g/l 29.5 28.1 32.7
Pleural fluid LDH, U/l 187 184 179
Glucose, mmol/l 6.42 6.24 7.47
Pleural fluid protein/Serum protein 0.43 0.4 0.51
Pleural fluid LDH/Serum LDH 0.62 0.62 0.55
Pleural fluid LDH > 2/3 of Serum LDH ULN No No No
LDH lactate dehydrogenase, ULN upper limit of normal
Table 4 Right-sided heart catheterization
Date 12 October 2015 16 November 2015
Parameter (pre-intervention) (post-intervention)
PAS, mmHg 84 55
PAD, mmHg 34 22
PAM, mmHg 53 34
CO, l/minute 4.07 5
CI, l/minute per m2 2.09 2.5
PVR, Wood units 12 4
CI cardiac index, CO cardiac output, PAD pulmonary artery diastolic pressure,
PAM pulmonary artery mean pressure, PAS pulmonary artery systolic pressure,
PVR pulmonary vascular resistance
Table 5 Six-minute walk test
Date 13 October 2015 16 November 2015
Distance, m 165 348
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Conclusions
PAH is a serious and life-threatening adverse effect of
long-term dasatinib use. Patients should always be
closely monitored when using dasatinib for a prolonged
time. Due to growing usage of dasatinib and novel appli-
cations in other diseases, overall awareness should be
raised, as the risk factors involved in the development of
PAH are still unclear. All cases should be reported to in-
crease our knowledge, and new studies regarding the
exact mechanisms should be conducted.
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